Chimerix (NASDAQ:CMRX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a $11.00 target price on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on CMRX. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research note on Thursday, November 7th.

Chimerix Price Performance

CMRX traded down $0.02 on Monday, reaching $1.02. 15,961 shares of the stock were exchanged, compared to its average volume of 353,305. The company’s 50-day moving average price is $0.90 and its 200 day moving average price is $0.91. The firm has a market capitalization of $91.43 million, a PE ratio of -1.11 and a beta of 1.13. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $1.26 million. During the same period last year, the business earned ($0.21) EPS. As a group, equities analysts forecast that Chimerix will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Chimerix

Institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC lifted its position in shares of Chimerix by 15.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 291,981 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 138,098 shares during the period. Marshall Wace LLP purchased a new position in Chimerix during the second quarter valued at $137,000. Valeo Financial Advisors LLC grew its position in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares during the period. Finally, Koshinski Asset Management Inc. purchased a new stake in shares of Chimerix during the first quarter worth about $42,000. 45.42% of the stock is owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.